Two-second acquisition
comfortable for patients
Track diseases at the microscopic scale in the retina
"In follow-up examinations of AMD patients, the rtx1 enabled detecting the progression of atrophic lesions over a timescale of weeks, instead of months with conventional imaging."
Prof. Paques. Quinze-Vingts National Hospital, June 2020, Paris, France
"AO technology will likely contribute to faster and more cost effective drug development for the treatment of eye diseases."
Lin et al.
Invest Opth Vis Sc 2019, 60:4520-4531
"Adaptive optics (AO) ophthalmoscopy is now an accessible tool to visualize photoreceptors in the human living retina."
Cristescu et al.
Rom J Ophthalmol. 2019, 63:153-160.
"The rtx1 allowed us to directly observe stem-cell-derived RPE cells after their transplantation in a patient’s retina. We could verify that the mosaic arrangement of these cells was similar to that of natural RPE cells, and stable over time."
Dr. Takagi. Kobe City Eye Center, July 2019, Kobe, Japan
"Direct assessment of photoreceptors in RP patients by high-resolution imaging technologies is crucial for the future development of RP therapeutics."
Lin et al.
Invest Opth Vis Sc 2019, 60:4520-4531
"Several studies of human retinal photoreceptors in diabetic patients using Imagine Eyes’ AO retinal camera have been achieved."
Cristescu et al.
Rom J Ophthalmol. 2019, 63:153-160.
"The rtx1 demonstrates that, unlike the common belief, performing AO retinal imaging can be as easy as standard retinal imaging."
Prof. Paques.
Quinze-Vingt National Hospital, July 2018, Paris, France
"We, for the first time, visualized longitudinal changes during the recovery of cone photoreceptors in the eyes of VKH patients."
Nakamura et al.
Graefes Arch Clin Exp Ophthalmol 2018, 256:387-394
"The image resolution achieved by this technology is superior to that of any other current diagnostic tool."
Zaleska-Zmijewska et al.
Journal of Diabetes Research 2017, article ID 4174292
"Adaptive optics retinal imaging provided non-invasive and sensitive information on the pathologic disruption of the cone mosaic."
Ziccardi et al.
American J Ophthalmol 2015, 160:301-312
Imaging at the cellular level
When using the rtx1 Adaptive Optics Retinal Camera, you examine the retina at a scale where individual cells are visible. Its ultrahigh-resolution images reveal parafoveal cone photoreceptors as well as other microscopic retinal structures that cannot be seen with conventional techniques.
Microvascular imaging
The rtx1 enables visualizing the microscopic walls of retinal arterioles non-invasively. Focal narrowing, perivascular sheathing, micro-hemorrhages and micro-aneurisms are also visible without using contrast agents.
Imaging beyond photoreceptors
The TFI optional add-on extends the imaging capability of rtx1 for investigating retinal anatomy, pathology and therapy at the microscopic scale.
By using transscleral illumination, it enables the visualization of small retinal structures that are usually invisible in adaptive optics images, such as the retinal pigment epithelium.
Most existing rtx1 units can be upgraded with TFI.
Fast follow-up workflow
with micrometer precision
Cellular & microvascular biomarkers
quantify small retinal changes
Over 200 publications
in a wide range of pathologies
Tracking microscopic progression/regression
By design, the rtx1 delivers images that are free from motion distortion. Building on this advantage, its software enables capturing the same retinal region through different visits, and automatically aligns follow-up images. This allows tracking minute changes in a group of cells, a vessel section, or a lesion over time.
Cellular biomarkers
With AOdetect application, rtx1 delivers an array of candidate biomarkers for assessing the distribution of parafoveal cone cells :
- Voronoi cell density
- Inter-cell spacing
- Regularity index
- Dispersion index
On follow-up images, AOdetect enables analyzing the exact same region of interest, for monitoring a given group of cells over time.
Microvascular biomarkers
AOdetect application also provides supervised image segmentation for analyzing the wall morphology of blood vessels. With this option, rtx1 delivers non-invasive vascular structure metrics with micrometer precision:
- Internal and external diameter
- Wall thickness
- Wall Cross Section Area (WSCA)
- Wall to Lumen Ratio (WLR)
The exact same vascular section is assessed on follow-up images with a only a few clicks.
Clinician-friendly
The time when AO technology could only be mastered by physicists and engineers belongs to the past. Designed in collaboration with clinicians, the rtx1 is driven by user-friendly software which enables high patient throughput. It is also comfortable for patients as image acquisition uses infrared illumination and only takes 2 seconds.
Reference product
The rtx1 stands out as the most widely-used AO imaging device in medical centers throughout the world. Cleared by regulatory authorities in several countries, and proven by over 200 peer-reviewed publications, it has become the reference product for cellular-resolution retinal imaging.
Links & Downloads
Specifications
| Imaging type | En face reflectance imaging |
| Detection type | Low-noise CCD camera |
| Illumination | Near infrared LED, 850nm |
| Exposure time | < 10 ms |
| Imaging field of view 1 | 4° x 4° |
| Fixation stimulation range | H ± 14.5° / V ± 10° |
| Camera pixel pitch on the fundus 1 | 1.1 µm |
| Optical resolution on the fundus 1, 2 | 250 line pairs per millimeter (lppmm) |
| Adaptive optics control | Fully automated, resistant to blinking and movement |
| Depth focussing range 1 | 1600 µm |
| Pupil diameter | ≥ 4 mm |
| Refractive error compensation | -12 to +6 D |
| Total footprint (WxDxH) | 137x53x132-162 cm |
1 Some specifications are dependent on several factors including but not limited to: ocular biometry, pupil diameter, optical defects, ocular media transparency.
2 The system can image line pairs of 2 µm in line width.
rtx1 is a certified medical device of class IIa in the European Union. rtx1 is an approved medical device in Japan, China and Korea. In the USA, rtx1 has not received FDA clearance; it is an investigational device that requires Institutional Review Board (IRB) oversight.
rtx1 with AOdetect is certified in the European Union, Japan and Korea. rtx1 with TFI is certified in the European Union.
In other territories, rtx1 with AOdetect or TFI are separate products for research use only.
For use by trained eyecare professionals only.
All retinal images on this page are courtesy of: Quinze-Vingts National Eye Hospital, Paris, France.